New study on risk of cancer among diabetes patients registered in the EU PAS Register

19.12.2016 PASS DiabCancer – Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study. Study accepted in the EU PAS Register. More detailed information about the study available here.